Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
ARISTOTLE CORP (ARTL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/19/2021 |
GN
| Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development |
| 03/11/2021 |
GN
| Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd |
| 03/09/2021 |
GN
| Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors |
| 03/02/2021 |
GN
| Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th |
| 02/17/2021 |
GN
| Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal |
| 02/08/2021 |
GN
| Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants |
| 01/29/2021 |
GN
| Artelo Biosciences to Present at the LSX World Congress Virtual Conference |
| 01/05/2021 |
GN
| Artelo Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference |
| 12/09/2020 |
GN
| Artelo Biosciences Files Patent Application for New Formulation of ART27.13 |
| 12/08/2020 |
GN
| Artelo Biosciences to Present at The 13th Annual LD Micro Main Event Conference on December 15th |
| 11/23/2020 |
GN
| Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs |
| 11/16/2020 |
GN
| Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss |
| 11/04/2020 |
GN
| Artelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update |
| 10/21/2020 |
GN
| Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders |
| 10/14/2020 |
GN
| Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters' Option |
| 10/09/2020 |
GN
| Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering |
| 09/29/2020 |
GN
| Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia |
| 09/11/2020 |
GN
| Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th |
| 07/14/2020 |
GN
| Artelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update |
| 06/29/2020 |
GN
| Artelo Biosciences Expands Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds |
| 06/03/2020 |
GN
| Artelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences |
| 05/12/2020 |
GN
| Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal |
| 04/14/2020 |
GN
| Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update |
| 02/24/2020 |
GN
| Artelo Biosciences to Present at Biocom's 10th Annual Global Life Sciences Partnering Conference |
| 01/29/2020 |
GN
| Artelo Biosciences to Present at the LSX World Congress in London |
| 01/14/2020 |
GN
| Artelo Biosciences Reports First Quarter Fiscal Year 2020 Financial Results and Provides Business Update |
| 11/25/2019 |
GN
| Artelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update |
| 11/18/2019 |
GN
| Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal |
| 07/15/2019 |
GN
| Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update |
| 06/21/2019 |
GN
| Artelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq |
| 11/19/2009 |
4
| NETTER DONALD T (Director) has filed a Form 4 on ARISTOTLE CORP|
Txns:
| Disposed/sold 1,000 shares
@ $0
Disposed/sold 52,417 shares
@ $0 |
|
| 11/18/2009 |
4
| SMITH H WILLIAM (V. P., Gen Counsel & Secretary) has filed a Form 4 on ARISTOTLE CORP|
Txns:
| Disposed/sold 10,000 shares
@ $0 |
|
| 11/18/2009 |
4
| SCHLIER BRIAN (Vice President) has filed a Form 4 on ARISTOTLE CORP|
Txns:
| Disposed/sold 15,000 shares
@ $0 |
|
| 11/18/2009 |
4
| JOHNSON DEAN T (Senior Vice President & C.F.O.) has filed a Form 4 on ARISTOTLE CORP|
Txns:
| Disposed/sold 20,000 shares
@ $0
Disposed/sold 2,300 shares
@ $0 |
|
|
|
|